These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30324481)

  • 21. Prognostic significance of hematological profiles in melanoma patients.
    Gandini S; Ferrucci PF; Botteri E; Tosti G; Barberis M; Pala L; Battaglia A; Clerici A; Spadola G; Cocorocchio E; Martinoli C
    Int J Cancer; 2016 Oct; 139(7):1618-25. PubMed ID: 27252119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASO Author Reflections: Treatment Approaches to Sinonasal Mucosal Melanoma.
    Amit M; Hanna EY
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):890-891. PubMed ID: 30267288
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.
    Ladányi A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):490-500. PubMed ID: 25818762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ASO Author Reflections: Metastatic Melanoma to the Large Bowel.
    Young CJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):675-676. PubMed ID: 30406486
    [No Abstract]   [Full Text] [Related]  

  • 26. 25-OH Vitamin D and Interleukin-8: Emerging Biomarkers in Cutaneous Melanoma Development and Progression.
    Ene CD; Anghel AE; Neagu M; Nicolae I
    Mediators Inflamm; 2015; 2015():904876. PubMed ID: 26504364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma.
    Garnier M; Zaragoza J; Bénéton N; Bens G; Meurisse V; Samimi M; Maillard H; Machet L
    J Am Acad Dermatol; 2018 Jul; 79(1):165-167.e2. PubMed ID: 29544740
    [No Abstract]   [Full Text] [Related]  

  • 28. ASO Author Reflections: Recurrence of Melanoma After a Negative Sentinel Node Biopsy-Predictors and Impact of Recurrence Site on Survival.
    Thomas DC; Han D
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):756-757. PubMed ID: 31571053
    [No Abstract]   [Full Text] [Related]  

  • 29. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
    Ohashi H; Takeuchi S; Miyagaki T; Kadono T
    Drug Discov Ther; 2020 Jul; 14(3):117-121. PubMed ID: 32595179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASO Author Reflections: The Sentinel Lymph Node in Melanoma: Now More Important Than Ever.
    Egger ME; McMasters KM
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):906-907. PubMed ID: 30311165
    [No Abstract]   [Full Text] [Related]  

  • 31. ASO Author Reflections: Melanoma Killed Bob Marley and Others Too.
    Asare EA; Stewart JH
    Ann Surg Oncol; 2021 Nov; 28(12):6994. PubMed ID: 34176059
    [No Abstract]   [Full Text] [Related]  

  • 32. Revisiting determinants of prognosis in cutaneous melanoma.
    Weiss SA; Hanniford D; Hernando E; Osman I
    Cancer; 2015 Dec; 121(23):4108-23. PubMed ID: 26308244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASO Author Reflections: Wait Times for Melanoma Surgery.
    Nessim C; Crawford AB
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):527-528. PubMed ID: 30515669
    [No Abstract]   [Full Text] [Related]  

  • 34. ASO Author Reflections: Limited Surgery Plus Radiotherapy for Melanoma Patients with Cervical Node Metastases.
    Thompson JF; Kroon HM
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):912-913. PubMed ID: 30367301
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
    Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
    Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ASO Author Reflections: Counseling Melanoma Survivors on the Risk of a Second Melanoma.
    Wiener AA; Schumacher JR; Neuman HB
    Ann Surg Oncol; 2022 Sep; 29(9):5933-5934. PubMed ID: 35524082
    [No Abstract]   [Full Text] [Related]  

  • 37. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma.
    Ladányi A; Somlai B; Gilde K; Fejös Z; Gaudi I; Tímár J
    Clin Cancer Res; 2004 Jan; 10(2):521-30. PubMed ID: 14760073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
    Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review.
    Lens MB; Newton-Bishop JA
    Ann Oncol; 2005 Mar; 16(3):460-5. PubMed ID: 15642704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASO Author Reflections: Optimizing the Outcomes for Patients: The Evolution of the Management of Regional Disease in Patients with Melanoma.
    Lowe MC; Farley CR; Delman KA
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):908-909. PubMed ID: 30298327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.